Pfizer (NYSE:PFE) Trading 1.8% Higher – Time to Buy?

Shares of Pfizer Inc. (NYSE:PFE) rose 1.8% during trading on Wednesday . The stock traded as high as $25.89 and last traded at $25.5950. Approximately 51,320,329 shares traded hands during trading, a decline of 0% from the average daily volume of 51,352,383 shares. The stock had previously closed at $25.15.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PFE. Guggenheim raised their target price on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, November 24th. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Citigroup began coverage on shares of Pfizer in a report on Tuesday. They issued a “neutral” rating and a $26.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.39.

Pfizer Trading Up 1.8%

The company has a market capitalization of $145.53 billion, a price-to-earnings ratio of 14.88 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The business’s 50-day simple moving average is $25.05 and its 200-day simple moving average is $24.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 7th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date was Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Raiffeisen Bank International AG increased its position in shares of Pfizer by 38.4% in the 1st quarter. Raiffeisen Bank International AG now owns 53,831 shares of the biopharmaceutical company’s stock valued at $1,357,000 after buying an additional 14,937 shares in the last quarter. Plan Group Financial LLC raised its stake in Pfizer by 51.7% during the 1st quarter. Plan Group Financial LLC now owns 54,284 shares of the biopharmaceutical company’s stock worth $1,376,000 after buying an additional 18,495 shares during the period. Finally, Thoroughbred Financial Services LLC lifted its holdings in Pfizer by 12.4% during the first quarter. Thoroughbred Financial Services LLC now owns 30,236 shares of the biopharmaceutical company’s stock worth $766,000 after acquiring an additional 3,339 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.